Transforming growth factor β from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes

Journal of Leukocyte Biology

Volumn 66, Issue 6, 1999, Pages 981-988

  Cook, Gordon ^b   Campbell, John D M ^a   Carr, Christine E ^b   Boyd, Kelly S ^b   Franklin, Ian M ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NONE

Author keywords

Cytokines; Immunity; Tumor

Indexed keywords

CONCANAVALIN A; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; BLAST CELL; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0033454740     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlb.66.6.981     Document Type: Article

References (33)

1. Hallek, M., Bergsagel, P. L. Anderson, K. C. (1998) Multiple myeloma: Increasing evidence of a multistep transformation process. Blood 91, 3-21.
2. Massaia, M., Attisano, C., Bianchi, A., Redoglia, V., Dianzani, U., Pileri, A. (1991) A peculiar state of T cell competence in human myeloma defined by HLA-DR expression and CD3 hyperreactivity. FASEB J. 5, A963.
3. Massaia, M., Bianchi, A., Dianzani, U., Camponi, A., Attisano, C., Boccadoro, M., Pileri, A. (1900) Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral-blood lymphocytes-T of patients with monoclonal gammopathies. Clin. Exp. Immunol. 79, 100-104.
4. Massaia, M., Borrione, P., Attisano, C., Barral, P., Beggiato, E., Montacchini, L., Bianchi, A., Boccadoro, M., Pileri, A. (1995) Dysregulated Fas and bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood 85, 3679-3687.
5. Janson, C. H., Grunewald, J., Osterborg, A., Dersimonian, H., Brenner, M. B., Mellstedt, H., Wigzel, H. (1991) Predominant T cell receptor V gene usage in patients with abnormal clones of B cells. Blood 77, 1776-1780.
6. + T cell expansions are found preferentially in patients with a low tumour burden. Eur. J. Immunol. 27, 2245-2252.
7. Dianzani, U., Pileri, A., Boccadoro, M., Palumbo, A., Dioppo, P., Bianchi, A., Camponi, A., Battazlio, S., Massaia, M. (1988) Activated idiotype reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood 72, 1064-1068.
8. Massaia, M., Bianchi, A., Attisano, C., Peola, S., Redoglia, V., Dianzani, U., Pileri, A. (1991) Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of CD3/TCR complex. Blood 78, 1770-1780.
9. Cimino, G., Avvisati, G., Amadori, S., Cava, M. C., Giannarelli, D., Di Nucci, G. D., Magliocca, V., Petrucci, M. T., Poti, G., Sgadari, C., Mandelli, F. (1990) High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. Br. J. Haematol. 75, 373-377.
10. Bertz, H., Burger, J. A., Kunzmann, R., Mertelsmann, R., Finke, J. (1997) Adoptive immunotherapy for multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukaemia 11, 218-283.
11. Kwak, L. W., Taub, D. D., Duffey, P. L., Bensinger, W. I., Bryant, E. M., Reynolds, C. W., Longo, D. L. (1995) Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345, 1016-1020.
12. Cook, G., Dunbar, M. M., Franklin, I. M. (1997) The role of adhesion molecules in multiple myeloma. Acta Haematol. 97, 81-89.
13. Schultze, J., Nadler, L. M., Gribben, J. G. (1996) B7-mediated costimulation and the immune response. Blood Rev. 10, 111-127.
14. Villunger, A., Egle, A., Marschitz, I., Kos, M., Bock, G., Ludwig, H., Geley, S., Kofler, R., Greil, R. (1997) Constitutive expression of Fas (APO-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumour-induced suppression of immune surveillance. Blood 90, 12-20.
15. Treon, S. P., Maimonis, P., Chauhan, D., Raje, Y. Teoh, G., Belch, A. R., Pilarski, L. M., Anderson, K. C. (1998) Soluble muc-1 (sMuc-1) is elevated in multiple myeloma (MM) bone marrow (BM) plasma and inhibits T cell proliferation. Blood 92 (Suppl. 1), 100a.
16. Urashima, M., Ogata, A., Chauchan, D., Hatziyanni, M., Vidriales, M. B., Dedera, D. A., Schlossman, R. L., Anderson, K. C. (1996) Transforming growth factor-β1: differential effects on multiple myeloma versus normal B cells. Blood 87, 1928-1938.
17. Bright, J. J., Kerr, L. W., Sriram, S. (1997). TGFβ inhibits IL-2 induced tyrosine phosphorilation and activation of Jak-1 and Stat 5 in T lymphocytes. J. Immunol. 159, 175-183.
18. Kotake, S., Schumacher, H. R., Wilder, R. L. (1996) A simple nested RT-PCR method for quantitation of the relative amounts of multiple cytokine mRNAs in small tissue samples. J. Immunol. Meth. 199, 193-199.
19. Steinberger, I., Ben-Bassat, H., Hochberg, E., Lorerboum-Galaski, H. (1997) Interleukin-2 receptor α, β and γ subunit expression as a function of B-cell lineage ontogeny: the use of IL-2-PK664glu to characterize internalization via IL-2 receptor subunits. Scand. J. Immunol. 46, 129-136.
20. Yi, Q., Dabadghao, S., Osterborg, A., Bergenbrant, S., Holm, G. (1997) Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells. Blood 90, 1960-1967.
21. + T cells. Nature Med. 4, 1377-1382.
22. Dao, T., Huleatt, J. W., Hinorgorani, R., Crispe, I. N. (1997) Specific resistance of T cells to CD95-induced apoptosis during S-phase of the cell cycle. J. Immunol. 159, 4261-4267.
23. Sanchez-Mateous, P., Sanchez-Madrid, F. (1991) Structure-function relationship and immunochemical mapping of external and intracellular antigenic sites on the lymphocyte activation inducer molecule, AIM/CD69. Eur. J. Immunol. 21, 2317-2352.
24. Mardiney, M., Brown, M. R., Fleisher, T. (1996) Measurement of T cell CD69 expression: a rapid and efficient means to assess mitogen or antigen-induced proliferative capacity in normals. Cytometry 26, 305-310.
25. Tesli, R., D'Ambrosio, D., De Maria, R., Santoni, A. (1994) The CD69 receptor: a multipurpose cell-surface trigger for haematopoetic cells. Immunol. Today 15, 479-483.
26. Castellanos, M. C., Munoz, C., Monotoya, M. C., Lara-Pezzi, E., Lopez-Cabera, M., de Landazuri, M. O. (1997) Expression of the leukocyte early activation marker antigen CD69 is regulated by the transcription factor AP-1. J. Immunol. 159, 5463-5473.
27. Tesli, R., Phillips, J. H., Lanier, L. L. (1989) T cell activation via Leu-23 (CD69). J. Immunol. 143, 1123-1128.
28. Tugores, A., Alonso, A. I., Sanchez-Madrid, F., de Landazuri, M. O. (1992) Human T cell activation through the activation inducer molecule. CD69 enhances the activity of transcription factor AP-1. J. Immunol. 148, 2300-2306.
29. Santis, A. G., Lopez-Cabrera, M., Sanchez-Madrid, K. Proudfoot, N. (1995) Expression of the early lymphocyte activation antigen CD69, a C-type lectin, is regulated by mRNA degradation associated with AU-rich sequence motifs. Eur. J. Immunol. 25, 2142-2146.
30. + T cell subset inhibits antigen-specific T cell responses and prevents colitis. Nature 389, 737-741.
31. O'Garra, A. (1998) Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8, 275-283.
32. Derynk, R., Goeddel, D. V., Ullrich, A., Gutterman, J. U., Williams, R. D., Bringman, T. S., Berger, W. H. (1987) Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumours. Cancer Res. 46, 707-712.
33. Jiang, X., Kanai, H., Hiromura, K., Sawamura, M., Yano, S. (1995) increased intraplatelet and urinary transforming growth factor-β in patients with multiple myeloma. Acta Haematol. 94, 1-6.